Search

ENPNewswire-November 14, 2016--Tolerability Data for Shire's Cuvitru Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting (C)2016 ENPublishing - http://www.enpublishing.co.uk Release date- 12112016 - [...]

Salt Lake City: Following is the Profile of Morgan Brown, MBA, CPA Executive Vice President and Chief Financial Officer of Lipocine Inc.: Mr. Morgan Brown has more than 20 years [...]

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites LEXINGTON, Massachusetts, September 14, 2016 /PRNewswire/ -- Shire plc [...]

Cranbury: Following is the Profile of Kenneth M. Bahrt, M.D., F.A.C.R. Chief Medical Officer of Oncobiologics, Inc.: Dr. Bahrt has served as our Chief Medical Officer since June 2015. Prior [...]

Cranbury: Following is the Profile of Patrik S. Florencio Esq. Chief Compliance Officer of Amicus Therapeutics, Inc.: Patrik Florencio joined Amicus Therapeutics in August 2015 as Chief Compliance Officer. Prior [...]

GLASSIA[Alpha-1 Proteinase Inhibitor (Human)] is the only FDA approved alpha-1 antitrypsin (AAT) augmentation treatment that patients can self-infuse at home LEXINGTON, Massachusetts and NESS ZIONA, Israel, June 15, 2016 /PRNewswire/ [...]

ZUG, Switzerland, June 10, 2016 /PRNewswire/ -- Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta New option to [...]

Dublin: Shire Plc has issued the following news release:Shire plc ('Shire') (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended March 31, 2016.Financial Highlights Q1 2016 Growth(1) [...]

Proposed combination with Baxalta on track with shareholder votes set for May 27 and closing anticipated in early June 2016 DUBLIN, April 29, 2016 /PRNewswire/ -- Shire plc ('Shire') (LSE: [...]

(EDGAR Online via COMTEX) -- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of [...]

(EDGAR Online via COMTEX) -- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of [...]

(EDGAR Online via COMTEX) -- ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with Shire's unaudited consolidated [...]

Apr 20, 2015 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned [...]

Apr 13, 2015 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned [...]

Apr 06, 2015 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned [...]

Natpara to be distributed through select group of specialty pharmacies and supported by comprehensive patient support services LEXINGTON, Massachusetts, April 1, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) [...]

Mar 26, 2015 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned [...]

Mar 19, 2015 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned [...]

(EDGAR Online via COMTEX) -- XLRN-2015.03.02.form8-k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------------------------------------------------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

Washington, DC, Feb 23, 2015 (MidnightTrader via COMTEX) -- American depositary receipts of Shire plc (SHPG) were trading 1.52% higher at $240.90 Monday afternoon after saying it has completed its [...]

Feb 23, 2015 (MarketLine Financial Deals Tracker via COMTEX) -- Shire plc has acquired all of the outstanding shares of NPS Pharmaceuticals, Inc. (NPS Pharma) for $46 per share in [...]

DUBLIN, February 21, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals, Inc. [...]

NEW YORK, February 18, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Moments ago, Analysts Review released new research updates concerning several important [...]

DUBLIN, Ireland, February 12, 2015 /PRNewswire/ -- Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the year to December 31, 2014. Full Year Financial Highlights 2014 Growth(1) Product sales [...]

Editor Note: For more information about this release, please scroll to bottom. LONDON, February 6, 2015 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: [...]